What's in Qing XIe's pipeline?

Qing XIe has 3 drugs in our index: 0 marketed, 0 filed, 0 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Qing XIe's portfolio?

Top competitors by shared drug class: Hospices Civils de Lyon, Iran Hepatitis Network, Sang Gyune Kim.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/qing-xie.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Qing XIe — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Qing XIe pipeline: 0 marketed, 0 filed, 0 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

0 marketed 0 filed 0 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

No leading-phase drugs tracked for this sponsor.

Therapeutic area mix

Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Hospices Civils de Lyon · 1 shared drug class
Iran Hepatitis Network · 1 shared drug class
Sang Gyune Kim · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Qing XIe:

Cite this brief

Drug Landscape (2026). Qing XIe — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/qing-xie. Accessed 2026-05-17.